ASIT biotech (ASIT) - No surprises in FY18 annual report

11:51 EDT 17 May 2019 | Edison Investment Research

Edison Investment Research - Pharmaceuticals & healthcare - ASIT biotech: ASIT biotech published its preliminary FY18 results in early April, including the cash position at the end of March 2019, and issued its FY18 report in May. The release of the balance of the FY18 financial statements resulted in no surprises, while the completion of the dosing phase of the Phase III study implies a safe and well-tolerated short-course allergy product.
ISIN: BE0974289218

Original Article: ASIT biotech (ASIT) - No surprises in FY18 annual report


More From BioPortfolio on "ASIT biotech (ASIT) - No surprises in FY18 annual report"

Quick Search


Relevant Topics

BioPortfolio - life science, medical devices and pharmaceutical conference
BioPortfolio is a leading news, information and knowledge resource covering the global life science industries impacted on by biotechnology. The site aims to provide the lay person, the researcher and the management executive with a single location to so...

Health care (or healthcare) is the diagnosis, treatment, and prevention of disease, illness, injury, and other physical and mental impairments in humans. Health care is delivered by practitioners in medicine, chiropractic, dentistry, nursing, pharmacy, a...

Biotechnology - Biotech
"using living things to create products or to do tasks for humans" About Biotechnology - Biotech Biotechnology is the practice of using plants, animals and micro-organisms such as bacteria, as well as biological processes - such as the ripen...